Producción CyT

Medicina - Oligo-fucoidan enhances the therapeutic efficacy of Boron Neutron Capture Therapy (BNCT) in the oral cancer and ectopic colon cancer experimental models

Congreso

Autoría:

MONTI HUGHES, ANDREA ; , V.A. Trivillin* ; , J.A. Goldfinger ; , E.C.C. Pozzi, ; S. Thorp, ; P. Curotto, ; , M.A. Garabalino ; , M.E. Itoiz ; , I.S. Santa Cruz ; , P.S. Ramos ; , A.E. Schwint.

Fecha:

2018

Editorial y Lugar de Edición:

BsAs

ISSN:

0025-7680

Resumen *

Introduction BNCT combines selective tumor uptake of 10-B compounds and neutron irradiation. We demonstrated the therapeutic effect of BNCT in the hamster cheek pouch oral cancer and BDIX rat ectopic colon cancer models. We also studied the radiotoxic effects of BNCT, mucositis and dermatitis, respectively. Oligo-Fucoidan is extracted from seaweeds and has exhibited anticancer and anti-inflammatory properties. The aim of the present study is to evaluate the radioprotective and therapeutic effect of Oligo-Fucoidan+BNCT in both cancer models. Materials and Methods BDIX rats were injected subcutaneously in the right hind flank with DHD/K12/TRb syngeneic colon cancer cells. The tumor-bearing legs were treated locally with BNCT mediated by BPA (boronophenylalanine) at RA-3 Nuclear Reactor, with or without Oligo-Fucoidan (200mg/ml, oral administration during 16 days). Cancerized hamster cheek pouches (DMBA in mineral oil, applied twice a week for 8 weeks) were exposed to BPA-BNCT with or without Oligo-Fucoidan (200mg/kg, 16 days). Results Oligo-Fucoidan was nontoxic. It did not reduce the percentage of animals with severe dermatitis or mucositis, but it did enhance BNCT therapeutic effect on tumors. BDIX rats treated with BNCT+Oligo-Fucoidan exhibited a mean ratio tumor volume Post-BNCT/Pre-BNCT significantly lower than the BNCT group (0.35±0.31 vs 1.09±0.76 respectively, p= 0.0002). In the oral cancer model, BNCT+Oligo-Fucoidan group exhibited a higher Overall tumor response than the BNCT group and also enhanced tumor complete response (94% vs 67%; 71% vs 41% respectively). Conclusion Oligo-Fucoidan enhances the therapeutic efficacy of BNCT in the hamster oral cancer model and BDIX rat ectopic colon cancer model. Acknowledgments We gratefully acknowledge the provision of Oligo-Fucoidan by Hi-Q Marine Biotech International Ltd (Taiwan), and the efforts of Ming-Chen Hsiao to promote these studies. Información suministrada por el agente en SIGEVA

Palabras Clave

Oligo-fucoidanOral cancer modelEctopic colon cancer modelBNCT